Cargando…
Increased adherence eight months after switch from twice daily calcineurin inhibitor based treatment to once daily modified released tacrolimus in heart transplantation
BACKGROUND: Modified-release tacrolimus (TAC) is a new, once-daily oral formulation of the established immunosuppressive agent TAC. This study evaluated long-term patient adherence, as well as safety and efficacy, in stable patients after heart transplantation (HTx) who switched from a conventional...
Autores principales: | Doesch, Andreas O, Mueller, Susanne, Akyol, Ceylan, Erbel, Christian, Frankenstein, Lutz, Ruhparwar, Arjang, Ehlermann, Philipp, Dengler, Thomas J, Katus, Hugo A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3808207/ https://www.ncbi.nlm.nih.gov/pubmed/24174870 http://dx.doi.org/10.2147/DDDT.S52820 |
Ejemplares similares
-
Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograft recipients: a long-term follow-up study
por: Doesch, Andreas O, et al.
Publicado: (2013) -
Once– versus twice–daily tacrolimus: are the formulations equivalent?
por: Ciszek, Michał
Publicado: (2013) -
Advantageous effects of immunosuppression with tacrolimus in comparison with cyclosporine A regarding renal function in patients after heart transplantation
por: Helmschrott, Matthias, et al.
Publicado: (2015) -
Superior rejection profile during the first 24 months after heart transplantation under tacrolimus as baseline immunosuppressive regimen
por: Helmschrott, Matthias, et al.
Publicado: (2014) -
Efficacy and safety of once daily tacrolimus compared to twice daily tacrolimus after liver transplantation
por: Bzeizi, Khalid Ibrahim, et al.
Publicado: (2021)